Text Size

Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers

Sutton A., Gouws P., Ropo A.


  • 2008
  • International Journal of Clinical Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Guildford Clinical Pharmacology Ltd., Technology Center, Guildford, Surrey, United Kingdom; Conquest Hospital, Ridge, St. Leonards-on-Sea, East Sussex, United Kingdom; Santen Oy Clinical Research, Tampere, Finland; Cedars Vanzell Road, Midhurst, West Sussex GU29 9BA, United Kingdom

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.


A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.


Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022